Results: The MAF was higher for the rs2808630_G allele (P ‫؍‬ 0.03) and lower for the rs1205_A allele (P ‫؍‬ 0.03) in the AASK compared with NHANES III. Among AASK participants, the rs3093058_T allele predicted higher CRP concentrations (P < 0.0001) but not CKD progression. The rs2808630_GG genotype was associated with higher risk of the composite endpoint compared with the AA genotype (P ‫؍‬ 0.002). Participants with the rs2808630_GG genotype on angiotensin converting enzyme inhibitors (ACEIs) versus ␤ blockers had increased risk of progression (P ‫؍‬ 0.03).
F amilial clustering of chronic kidney disease (CKD) and ESRD has been reported in populations throughout the world for most types of nephropathy (1) (2) (3) (4) (5) (6) . This genetic predisposition to ESRD seems to be strongly associated with race (7, 8) . Compared with people with no family history of kidney disease, African Americans with a first-degree relative with ESRD have a nine-fold increase in the risk of ESRD compared with a three-to five-fold increase in whites (8) . Recently, the candidate gene MYH9 has been identified as associated with nondiabetic ERSD in African Americans, and this association explains some of the disparity in incidence of ESRD observed between whites and African Americans (7, 9) . However, it is possible that additional genetic variants, such as those related to inflammatory pathways, may also be associated with ESRD.
Biomarkers of inflammation, including C-reactive protein (CRP), are increased even in early stages of CKD and have been linked to the risk of CKD progression (10 -15) . These observations have led to studies examining the genetic basis of inflammation and identification of several candidate genes for ESRD susceptibility (16 -19) . Recently, several large population-based studies showed that plasma CRP levels are under genetic influence (20 -25) . Some of these polymorphisms have been consistently associated with CRP levels (higher levels associated with rs3093058_T and lower levels associated with rs1205_A and rs2808630_G) and the risk of cardiovascular events (rs3093058_T) in African Americans (23) .
CRP gene polymorphisms that affect CRP concentrations may reflect lifetime exposure to CRP more accurately than single time point measurements of serum CRP concentrations. The primary goal of this study was to characterize CRP gene polymorphisms and evaluate their association with CKD progression. We hypothesized that polymorphisms associated with higher levels of CRP would be associated with higher risk of CKD progression. Additionally, we examined whether these polymorphisms modify the renoprotective effects of angiotensin converting enzyme inhibitors (ACEIs), a drug class known to have anti-inflammatory effects (26 -28) . We hypothesized that patients with polymorphisms associated with higher levels of CRP would benefit most from ACEIs.
Materials and Methods

Study Participants
This study included participants from the African-American Study of Kidney Disease and Hypertension (AASK) trial and The Third National Health and Nutrition Examination Survey (NHANES III). The AASK design and results have been previously described (9, 29) . Briefly, participants were self-identified African American, 18 to 70 yr, with hypertension defined by diastolic BP Ͼ95 mmHg and a GFR between 20 and 65 ml/min per 1.73 m 2 , measured by I 125 iothalamate clearance.
Exclusion criteria included (1) identifiable cause of CKD other than hypertension; (2) diabetes mellitus (DM); (3) urine protein/creatinine ratio Ͼ2.5; (4) accelerated or malignant hypertension within 6 mo; (5) secondary hypertension, (6) serious illness; and (7) specific contraindication to a study drug. The protocol for genetic testing was approved by the institutional review board at each center, and written informed consent was obtained. Similarly, an Ethical Review Committee from the CDC was obtained for the NHANES III genetic information.
The AASK trial followed a 3 ϫ 2 factorial design. Participants were randomized to ␤ blockers (BBs; metoprolol 50 to 200 mg/d), calcium channel blockers (CCBs; amlodipine, 5 to 10 mg/d), or an ACEI (ramipril, 2.5 to 10 mg/d) and to two levels of BP: low (mean arterial pressure [MAP] goal of Ͻ92 mmHg) or usual (MAP 102 to 107 mmHg) (29) . Data were collected for the following comorbidities: cancer, liver disease, congestive heart failure, left ventricular hypertrophy, arrhythmias, and cardiovascular disease. An interim analysis at 3 yr halted the amlodipine arm because patients with proteinuria (Upr/Cr Ͼ 0.22) taking amlodipine had faster GFR decline. DNA samples were available for 670 AASK participants that entered the trial. Serum CRP concentrations were measured in the AASK participants by nephelometry using a high-sensitivity assay (Dade Behring BN I). All measurements were done by a central laboratory at the Cleveland Clinic laboratory.
The NHANES are surveys conducted by the Centers for Disease Control to provide national estimates of the health of the U.S. civilian noninstitutionalized population. In the second phase of NHANES III conducted between 1991 and 1994, DNA samples were collected from 7159 consenting participants. We used genetic data from NHANES III participants that were self-identified African American, had GFR Ͼ60 ml/min, did not have DM, and had a UP/Cr ratio Ͻ2.5. For the NHANES III, we defined DM as self-reported physician diagnosis of DM, use of DM medications, fasting glucose Ͼ126 mg/dl, or a random glucose Ն200 mg/dl.
CRP Polymorphism Genotyping
Five tag single nucleotide polymorphisms (SNPs) were selected based on variation data for 23 European Americans and 24 African Americans resequenced by Seattle SNPs (pga.gs.washington.edu) (21, 30) using LDSelect at default settings (r 2 Ͼ 0.64): rs1417938, rs1205, rs2808630, rs3093058, and rs3093066. We also selected rs1800947 given previous reports of its association with decreased CRP levels. Genotyping was performed using TaqMan Assays By Design (Applied Biosystems, Foster City, CA) under standard conditions. All markers had a 95% or higher genotyping efficiency.
Outcomes
The main outcome for the AASK and for this study was a composite endpoint of (1) GFR event defined as halving of the baseline GFR or a drop in the GFR Ն 25 ml/min per 1.73 m 2 , (2) ESRD, or (3) death. GFR was measured at baseline, at 3 mo, and every 6 mo thereafter. The follow-up of the trial ranged from 3.5 to 6.5 yr. Additionally, we compared at baseline the allele frequencies of each SNP in the AASK participants with those in the African Americans from the NHANES III with normal kidney function as described previously (21) .
Statistical Analysis
All analyses were completed using SAS/Genetics 9.1 (SAS Institute, Cary, NC) and STATA 9 (College Station, TX). Each of the CRP SNPs was assessed to determine whether the observed genotype frequencies were in Hardy-Weinberg equilibrium. Marker-marker linkage disequilibrium was assessed using r 2 , calculated for all pairwise SNP comparisons in the AASK dataset. We considered significance for a two-sided ␣ ϭ 0.05 for all analyses and adjusted ␣ ␣/n 0.05/11 ϭ 0.0045 after Bonferroni's correction for the number of genotype comparisons. CRP was log-transformed, and the distribution was checked for normality. Cox proportional hazards and Kaplan Meier plots were used to test the association between SNP and the composite outcome. Variables were selected a priori for the multivariate analysis. Haplotypes were inferred from tagSNPs using the expectation-maximization algorithm provided by SAS/Genetics 9.1, which also provides the probabilities for each individual's inferred haplotype pair for subsequent regression analyses. Common haplotypes (Ͼ5% frequency) were determined from the most likely pair of haplotypes inferred by the expectation-maximization algorithm. This study was an ancillary study to AASK, and as such, the analyses were not performed by the AASK Data Coordinating Center.
Results
Participant baseline characteristics are shown in Table 1 . One hundred fifty-two individuals (24%) reached the composite endpoint: 109 experienced a GFR event, 80 reached ESRD, and 12 patients died.
CRP Allele and Genotype Frequencies
The observed genotype distribution for the six CRP SNPs was consistent with Hardy-Weinberg equilibrium. The allele frequencies for CRP SNPs in AASK and NHANES III cohorts are presented in Table 2 . Participants in the AASK trial had a higher minor allele frequency (MAF) for rs2808630 (G allele: 17 versus 14% P ϭ 0.03) and a lower MAF for rs1205 (A allele: 18 versus 21%, P ϭ 0.03) compared with the African Americans from the NHANES III with normal kidney function, no DM, and a UP/Cr ratio Ͻ2.5; however, this association did not remain significant after adjusting for multiple comparisons (␣/n 0.05/6 ϭ 0.008). AASK participants also had a higher MAF for rs3093058 (T allele: 19 versus 16%); however, this did not reach statistical significance (P ϭ 0.08). Table 3 shows the genotype frequencies for each polymorphism for NHANES III and AASK participants. 0.45, 1.81), respectively. The rs3093058 genotypes AT and TT were associated with significantly higher levels of CRP in the AASK cohort (P Ͻ 0.001) compared with the AA genotypes (Table 4 ). The P value remained significant after Bonferroni's correction for 11 comparisons. No other tested CRP polymorphism was associated with CRP levels. Low: 50.15% (n ϭ 322); Usual: 49.9% (n ϭ 320) Drug assignment ACE inhibitor 41% (n ϭ 265) Low BP: 52%(n ϭ 138)/Usual BP: 48%(n ϭ 127) ␤ blocker 39% (n ϭ 252) Low BP: 50%(n ϭ 125)/Usual BP: 50%(n ϭ 127) Calcium channel blockers 19% (n ϭ 125) Low BP: 47%(n ϭ 59)/Usual BP: 53%(n ϭ 66) Figure 1 ). The P value remained significant after Bonferroni's correction for 11 comparisons (adjusted significance level ␣/n 0.05/11 ϭ 0.0045). Potential confounding variables were determined a priori, including age, gender, comorbidities, BP treatment assignment, baseline GFR, proteinuria, body mass index, smoking, and CRP levels. None of the other tested polymorphisms were associated with the composite endpoint. There were no statistically significant differences in the demographic or clinical characteristics among the different rs2808630 genotypes (Table 6 ). Other independent predictors for the composite endpoint in the model for the SNP rs2808630 included ACEI use, smoking, baseline proteinuria, and baseline GFR (Table 7) .
CRP Levels and Clinical Outcomes
The median CRP in the AASK participants involved in this study was 0.50 mg/dl (IQR, 0.22, 0.93). The median CRP levels were higher in women compared with men (0.60 versus 0.41 mg/dl, P Ͻ 0.0001), consistent with observations in the general population (31) . In this study, CRP level did not predict CKD progression as reflected by the combined endpoint (HR, 0.94; 95% CI, 0.80 to 1.10; P ϭ 0.4).
CRP Genotypes and ACEI Use
Pharmacogenomic analysis was performed to evaluate the effect of ACE inhibition within each rs2808630 genotype. There was no statistical difference between the three drugs and their effect on the composite outcome. We restricted our analyses to individuals with UP/Cr Ͼ0.22 based on the findings from the original trial in which the benefit of ACEI was the strongest in this group (9, 29) . Patients randomized to ACEI therapy in the setting of a baseline UP/Cr Ͼ0.22 experienced fewer composite endpoints than those assigned to CCBs (46 versus 54%; HR, 0.53; 95% CI, 0.31 to 0.91; P ϭ 0.02) and not significantly different than those assigned to BBs (46 versus 51%; HR, 0.89; 95% CI, 0.57 to 1.30; P ϭ 0.6). For the most common genotype, rs2808630 AA with UP/Cr Ͼ0.22 (n ϭ 128), ACEI therapy was superior to CCBs (HR, 0.33; 95% CI, 0.17 to 0.67; P ϭ 0.002) and similar to BBs (HR, 1.35; 95% CI, 0.75 to 2.43; P ϭ 0.3; Figure 2A ). For all individuals with the rs2808630_GG genotype (n ϭ 15), those allocated to ACEI therapy had a higher rate of progression than those allocated to BBs (HR, 5.34; 95% CI, 1.00 to 28.3; P ϭ 0.04; Figure 2B ). We were unable to divide the rs2808630_GG genotype by protein excretion because of the small number of individuals with UP/Cr Ͼ0.22 and the genotype of interest (n ϭ 6). There was statistical evidence to support effect modification by an interaction between ACEI and rs2808630 genotype and the composite outcome (P for the interaction ϭ 0.007).
Haplotype Analyses, CRP Levels, and Clinical Outcomes
Six common haplotypes were inferred from six CRP tagSNPs in the AASK participants (Table 8 ). The rs1800947 SNP was dropped from the model because of the low MAF (Ͻ1%). We tested for an association between CRP levels and CRP haplotypes, and the results of the haplotype-based analyses mimic the single SNP analyses. The haplotype tagged by the T allele of rs3093058 (H2) was associated with higher levels of CRP (P Ͻ 0.0001). No CRP haplotype was associated with the composite endpoint.
Discussion
The primary goal of this study was to evaluate the role of CRP polymorphisms in CKD progression. AASK represents an ideal population to study these associations because CKD progression occurs four times faster in African Americans (32) . Although our study suggests that some common mechanisms/ genetic susceptibilities to ESRD may share a common pathway, it is important to acknowledge that distinct renal diseases may involve other independent factors. Our study is performed in a cohort of African Americans with hypertensive kidney disease. Our results showed that CRP SNP rs3093058 was associated with increased levels of CRP in the CKD population (TT versus AT and AA genotypes) and is consistent with what has been shown in the general population (20 -24) .
Although the frequency of the rs3093058 T allele, which is associated with increased CRP levels, was marginally higher in the AASK population than community controls, this was not statistically significant. More importantly, we found no association between this allele and CKD progression. On the other hand, we showed a strong association between the rs2808630_GG genotype, which has been associated with lower levels of CRP (21, 22) , and both baseline CKD (higher in AASK than in controls) and CKD progression, as reflected by the composite endpoint. Additionally, we showed that individuals with this genotype assigned to ACEI progressed faster than those assigned to BBs. Haplotypes with estimated frequency of Ͻ5% were excluded from analysis. The lack of association observed between the T allele of the rs3093058, which tags a promoter variation rs3093062 (20, 21) , and CKD progression could be explained by a lack of statistical power to detect the small increase in risk of CKD in African Americans. Alternatively, it is possible that rs3093058 is not a key pathogenic mediator for CKD in this population. Although epidemiologic data support the role of inflammation, including CRP in the pathogenic process (11, (13) (14) (15) , CRP is a surrogate marker of the inflammatory process (33) . CKD patients have a high burden of comorbidities, and reverse causation may explain the associations with CRP. However, studies of non-CRP inflammatory cytokine gene polymorphisms could provide a link between inflammatory genes and pathways with CKD.
The underlying mechanisms regarding the association between the GG genotype of the rs2808630 and the composite endpoint in this study remains unclear. Despite adjustment for multiple comparisons, it is possible that this association represents a false-positive finding. A potential explanation is that the GG genotype of the rs2808630 is in linkage disequilibrium with another functional SNP associated with ESRD not genotyped directly in our study. Using the Genome Variation Server (gvs.gs.washington.edu/GVS/), we surveyed a 50-kb region surrounding rs2808630 for SNPs in high linkage disequilibrium with the rs2808630 in the West African samples from the International HapMap Project (34) . No SNP was in high linkage disequilibrium (defined as r 2 Ͼ 0.80), and 12 intergenic SNPs were in moderate linkage disequilibrium (defined at r 2 Ͼ 0.50). Fine mapping and functional studies will be needed to identify the causal SNP underlying the association described here.
It is possible that rs2808630 is the causal SNP and affects the response to reno-protective interventions. Our hypothesis was that individuals with chronic inflammation will benefit the most from ACEIs (26 -28,35) . Albeit small sample size, individuals with the most common genotype AA and UP/Cr ratio Ͼ0.22 benefited from ACEIs. Individuals with the less common genotype, GG (low inflammatory profile), were at an increased risk for the primary endpoint even when allocated to ACEIs compared with BBs (9). These findings should be considered preliminary and need to be confirmed in larger studies.
The main strength of our study is that it was performed in an randomized controlled trial primarily designed to address CKD progression, and therefore, outcome ascertainment was optimal. GFR, for example, was performed using the gold standard iothalamate clearance. Also, the longitudinal nature of the study allowed us to evaluate the genotype effect in disease progression among high-risk patients with CKD stages 3 and 4.
Our study is not without limitations. First, our study results are limited to African Americans with hypertensive CKD and cannot be extrapolated to other populations or other diseases. In addition, neither the AASK nor the NHANES III dataset currently has ancestry informative markers to adjust for admixture. Our main focus is CKD progression within the AASK cohort, which was a multicenter study across the nation, and ancestry background should be similar. However, admixture markers will need to be performed in the AASK cohort for future comparisons with other populations.
Finally, a limitation of our study is the lack of replication for the association of CRP polymorphisms and CKD progression in other independent cohorts. However, our study represents an independent replication for the association of CRP polymorphisms with CRP levels (21, 22, 24) . Independent replication studies in racially diverse CKD progression cohorts will be necessary to substantiate the new findings.
In conclusion, CRP SNPs that are associated with higher levels of CRP were more common in African Americans with hypertensive CKD than in African Americans without CKD; however, these SNPs were not associated with CKD progression. Additionally, we showed an association between the rs2808630_GG genotype (low inflammatory profile) with both baseline CKD and the risk of CKD progression and potential loss of renal benefit from ACEIs. Larger studies in African Americans are needed to further explore the role of CRP polymorphisms in response to ACEI and CKD progression.
